WAC™ Fragment screening technology: Principles & Advantages
In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
integrated drug discovery
Aqilion’s TAK1 inhibitor secures alliance worth € 950 million
Using an integrated drug discovery approach, first-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
LundaGUARD – A Consortium For Fighting Infectious Agents
Several private and public organizations join efforts in the LundaGUARD consortium to respond to present and future threats from infectious…